Biotech · Private company · Morristown, NJ, US

Park Therapeutics, Inc.

Track this companyFree. Adds Park Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards1

Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)Fiscal year 2024 · $3.3MNIH RePORTER 5UG3DA059285-02 · fetched Nov 12, 2026